147 related articles for article (PubMed ID: 30567199)
1. Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness.
Arora N; Gupta A; Li HC; Sadeghi N
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567199
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah's Witness patient.
Chojnowski K; Janus A; Bliźniewska K; Robak M; Treliński J
Transfusion; 2016 Oct; 56(10):2438-2442. PubMed ID: 27385671
[TBL] [Abstract][Full Text] [Related]
3. Novel approach to decrease platelet exposure in a pediatric Jehovah Witness patient.
Cruickshank A; Koury J
Pediatr Blood Cancer; 2019 Nov; 66(11):e27956. PubMed ID: 31397040
[No Abstract] [Full Text] [Related]
4. Acute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma.
Zhou L; Mohsen A; Khan MA; Guthrie T
J Chemother; 2014 Jun; 26(3):184-6. PubMed ID: 24621157
[TBL] [Abstract][Full Text] [Related]
5. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat.
Laszlo D; Agazzi A; Goldhirsch A; Cinieri S; Bertolini F; Rabascio C; Pruneri G; Calabrese L; Cocquio A; Martinelli G
Eur J Haematol; 2004 Apr; 72(4):264-7. PubMed ID: 15089764
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of acute myeloid leukaemia without blood transfusion in a member of Jehovah's Witnesses].
Larsen C; Jensen MK
Ugeskr Laeger; 2011 Nov; 173(46):2960-2. PubMed ID: 22094219
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
Perol L; Grignano E; Contejean A; Gastaud L; Legoff M; Franchi P; Deau-Fischer B; Willems L; Bouscary D; Tamburini J
Leuk Lymphoma; 2019 Sep; 60(9):2324-2327. PubMed ID: 30773115
[No Abstract] [Full Text] [Related]
8. Antineoplastic chemotherapy in Jehovah's Witness patients with acute myelogenous leukemia refusing blood products - a matched pair analysis.
Wilop S; Osieka R
Hematology; 2018 Jul; 23(6):324-329. PubMed ID: 29212421
[TBL] [Abstract][Full Text] [Related]
9. A single-institution experience of performing bloodless transplant in Jehovah's Witness patients.
Coltoff A; Shreenivas A; Afshar S; Steinberg A
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):44-49. PubMed ID: 30605629
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute leukaemia in adult Jehovah's Witnesses.
El Chaer F; Ballen KK
Br J Haematol; 2020 Sep; 190(5):696-707. PubMed ID: 31693175
[TBL] [Abstract][Full Text] [Related]
11. Acute leukaemia in Jehovah's Witnesses.
Cullis JO; Duncombe AS; Dudley JM; Lumley HS; Apperley JF; Smith AG
Br J Haematol; 1998 Mar; 100(4):664-8. PubMed ID: 9531331
[TBL] [Abstract][Full Text] [Related]
12. [Experience in kidney transplantation without blood transfusion: kidney transplantation transfusion-free in Jehovah's Witnesses. First communication in Mexico].
Hernández-Navarrete LS; Hernández-Jiménez JD; Jiménez-López LA; Budar-Fernández LF; Méndez-López MT; Martínez-Mier G
Cir Cir; 2013; 81(5):450-3. PubMed ID: 25125065
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.
Al-Nawakil C; Park S; Chapuis N; Dreyfus F; Szwebel TA; Gibault L; Molina T; Hermine O; Bouscary D; Tamburini J
Br J Haematol; 2012 Jan; 156(1):145-7. PubMed ID: 21848881
[No Abstract] [Full Text] [Related]
14. Romiplostim in chronic liver disease with severe thrombocytopenia undergoing an elective invasive procedure.
Castellote J; Girbau A; Arajol C; Xiol X
Rev Esp Enferm Dig; 2011 Oct; 103(10):556. PubMed ID: 22054278
[No Abstract] [Full Text] [Related]
15. Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia.
Berthelot-Richer M; Boilard B; Morin A; Bolduc B; Beauregard P; Kotb R
Transfusion; 2012 Apr; 52(4):739-41. PubMed ID: 22082044
[TBL] [Abstract][Full Text] [Related]
16. Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukemia.
Kerridge I; Lowe M; Seldon M; Enno A; Deveridge S
Arch Intern Med; 1997 Aug 11-25; 157(15):1753-7. PubMed ID: 9250237
[TBL] [Abstract][Full Text] [Related]
17. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature.
Donahue LL; Shapira I; Shander A; Kolitz J; Allen S; Greenburg G
Transfusion; 2010 Jul; 50(7):1561-7. PubMed ID: 20456679
[TBL] [Abstract][Full Text] [Related]
18. [Acute leukemia in Jehovah's Witnesses].
Bueno J; Zuazu J; Villalba T; Julià A
Sangre (Barc); 1999 Oct; 44(5):381-2. PubMed ID: 10618916
[TBL] [Abstract][Full Text] [Related]
19. Remissions after long-term use of romiplostim for immune thrombocytopenia.
Marshall AL; Scarpone R; De Greef M; Bird R; Kuter DJ
Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
[No Abstract] [Full Text] [Related]
20. What is the role of novel thrombopoietic agents in the management of acute leukemia?
Kuter DJ
Best Pract Res Clin Haematol; 2016 Dec; 29(4):372-378. PubMed ID: 27890262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
